A Comprehensive Exploration of the lncRNA CCAT2: A Pan-Cancer Analysis Based on 33 Cancer Types and 13285 Cases

Abstract EN

Whether the lncRNA CCAT2 expression level affects the clinical progression and outcome of cancer patients has not yet been fully elucidated.

There is still an inconsistent view regarding the correlation between CCAT2 expression and clinicopathological factors, including survival data.

Besides, the regulation mechanism of CCAT2 in human cancer is still unclear.

Our study analyzed a large number of publication data and TCGA databases to identify the association of CCAT2 expression with clinicopathological factors and to explore the regulatory mechanisms in human cancers.

We designed a comprehensive study to determine the expression of CCAT2 in human cancer by designing a meta-analysis of 20 selected studies and the TCGA database, using StataSE 12.0 to explore the relationship between CCAT2 expression and both the prognosis and clinicopathological features of 33 cancer types and 13285 tumor patients.

Moreover, we performed GO and KEGG pathway enrichment analyses on potential target genes of CCAT2 collected from GEPIA and LncRNA2Target V2.0.

The level of CCAT2 expression in tumor tissues is higher than that in paired normal tissues and is significantly associated with a poor prognosis in cancer patients.

Besides, overexpression of CCAT2 was significantly associated with tumor size, clinical stage, and TNM classification.

Meanwhile, CCAT2 expression is the highest in stage II of human cancer, followed by stage III.

Finally, 111 validated target gene symbols were identified, and GO and KEGG demonstrated that the CCAT2 validation target was significantly enriched in several pathways, including microRNAs in the cancer pathway.

In summary, CCAT2 can be a potential biomarker associated with the progression and prognosis of human cancer.